Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Bibliographic Details
Main Authors:	Y Chen, P Jobanputra, P Barton, S Bryan, A Fry-Smith, G Harris, R Taylor
Format:	Article
Language:	English
Published:	NIHR Journals Library 2008-04-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta12110

Similar Items

Celecoxib, etoricoxib, meloxicam, and nimesulide: comparison of their merits and demerits
by: Andrey Evgen'evich Karateev, et al.
Published: (2011-06-01)

Simultaneous determination of celecoxib, meloxicam and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations
by: Ya-Hui Hsieh, et al.
Published: (2006)

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
by: Yu Sue, et al.
Published: (2008-09-01)

Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis
by: Víctor Molina D, et al.
Published: (2014-09-01)

Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis
by: Víctor Molina D., et al.
Published: (2014-09-01)

The efficacy and safety of etoricoxib versus meloxicam in the treatment of patients with gonarthrosis
by: B V Zavodovsky, et al.
Published: (2016-12-01)

Etoricoxib in the treatment of osteoarthritis
by: S. G. Anikin, et al.
Published: (2020-03-01)

ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
by: A E Karateev
Published: (2009-06-01)

ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
by: A E Karateev
Published: (2009-06-01)

Etoricoxib for generalized osteoarthritis. Case report
by: I. S. Dydykina, et al.
Published: (2021-02-01)

Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach
by: Rozires P. Leão, et al.
Published: (2020-08-01)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
by: Notter Marianne, et al.
Published: (2008-03-01)

The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction.
by: John S Brownstein, et al.
Published: (2007-09-01)

Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway
by: Jeroen P. Jansen, et al.
Published: (2011-01-01)

Rofecoxib Attenuates the Pathogenesis of Amyotrophic Lateral Sclerosis by Alleviating Cyclooxygenase-2-Mediated Mechanisms
by: Yan-Hui Zou, et al.
Published: (2020-08-01)

Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
by: Chris Walker
Published: (2018-01-01)

Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat
by: Bernadette Lázár, et al.
Published: (2019-03-01)

LUMINESCENCE DETERMINATION OF ETODOLAC
by: A. V. Yegorova, et al.
Published: (2015-02-01)

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
by: Chris Walker
Published: (2019-01-01)

Rofecoxib Induced Purpura
by: Dogra Sunil, et al.
Published: (2004-01-01)

The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal
by: V. Benetello, et al.
Published: (2007-08-01)

Study of Osteoarthritis Treatment with Anti-Inflammatory Drugs: Cyclooxygenase-2 Inhibitor and Steroids
by: Hongsik Cho, et al.
Published: (2015-01-01)

Etodolac and the risk of acute pancreatitis
by: Liao Kuan-Fu, et al.
Published: (2017-03-01)

Ultrasound-assisted chiral derivatization of etodolac with (1R)-(−)-menthyl chloroformate for the determination of etodolac enanti
by: Yan Jin, et al.
Published: (2016-11-01)

Analysis of chiral non-steroidal anti-inflammatory drugs flurbiprofen, ketoprofen and etodolac binding with HSA
by: Chang-Chuan Guo, et al.
Published: (2011-08-01)

The effects of the selective cyclooxygenase-2 inhibitor rofecoxib & hypoxia on human colorectal cancer liver metastases : angiogenesis and prostaglandin metabolism
by: Chalmers, Claire Ritchie
Published: (2010)

In vivo study of the synovial membrane penetration index from celecoxib and etoricoxib and their impact on pain control in patients with inflammatory arthritis
by: Athina Theodoridou, et al.
Published: (2016-01-01)

Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
by: Xiaoting Feng, et al.
Published: (2018-01-01)

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis
by: Piet Geusens, et al.
Published: (2008-04-01)

The relative effectiveness of a non-steroidal anti-inflammatory medication (meloxicam) versus manipulation in the treatment of osteoarthritis of the knee
by: Tucker, Mark L.
Published: (2017)

Development and validation of HPLC and UV spectrophotometric methods for the determination of lumiracoxib in tablets
by: V. P. SOUSA, et al.
Published: (2009-05-01)

Development and validation of HPLC and UV spectrophotometric methods for the determination of lumiracoxib in tablets
by: T.S. Moreira, et al.
Published: (2008-09-01)

Pulmonary embolism in a woman taking oral contraceptives and valdecoxib.
Published: (2005-07-01)

Determination of Valdecoxib in Human Plasma Using Reverse Phase HPLC
by: Prafulla Kumar Sahu, et al.
Published: (2011-01-01)

Pulmonary embolism in a woman taking oral contraceptives and valdecoxib.
by: Elizabeth J Westgate, et al.
Published: (2005-07-01)

The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres
by: Thakral NK, et al.
Published: (2011-05-01)

A randomised placebo controlled trial of valdecoxib in the treatment of endometriosis
by: Carpenter, Tyrone Thomas
Published: (2005)

Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2
by: Han Jae, et al.
Published: (2008-11-01)

The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor on Noise- Induced Hearing Loss
by: Akram Pourbakht
Published: (2013-05-01)

Effects of Celecoxib (A Cyclooxygenase-2 Inhibitor) on Benign Prostatic Hyperplasia in Rat
by: Maryam Sarbishegi, et al.
Published: (2018-02-01)